Topic
12 stories from Planck Standard. Latest: September 6, 2026.
Marsh's summer survey found costs per employee would climb 11% if companies did nothing at all. Workers already paying about $5,300 a year are going to pay more in premiums and out of pocket both.
In mice engineered to carry human GLP-1 receptors, oral drugs orforglipron and danuglipron switched on the central amygdala and cut dopamine release during pleasurable eating — a pathway researchers had not expected them to touch.
A large BMJ study of people with type 2 diabetes found GLP-1 medications were associated with a notably greater risk of hair loss than rival drugs — though the shedding may be reversible.
A study of a decade of U.S. poison-center data found calls involving GLP-1 drugs jumped from roughly 1,500 a year to more than 8,000 after semaglutide's weight-loss approval — most of them preventable dosing errors.
Pharmaceutical companies bet on new approaches to crack into the lucrative weight loss market currently controlled by two industry giants.
The pharmaceutical giants are preparing to compete for senior customers as Medicare prepares to cover oral versions of popular weight-loss medications.
Research involving over 110,000 women found those taking Ozempic, Wegovy, and similar medications had significantly reduced cancer rates, though clinical trials are still needed.
University of Pennsylvania researchers discovered users frequently discuss menstrual irregularities, chills, and temperature changes not fully captured in clinical trials.
Copenhagen and Munich researchers reanalyzed 100+ studies and found regaining weight erases the benefits of a diet but does not leave a person metabolically worse off — overturning decades of public-health warnings.
Eli Lilly's GLP-1 generated $8.7 billion in Q1 sales versus Merck's $7.9 billion, ending Keytruda's three-year reign atop global drug-revenue rankings.
Orforglipron delivered 12.4% average body weight loss in trials and was approved in just 50 days — the fastest new drug approval since 2002 — at per month.
GLP-1 medications creating massive wardrobe refresh demand as millions shed pounds and seek new clothing options.